TRIB Fundamental Analysis - TRINITY BIOTECH PLC-SPON ADR

Name: TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock
Brand: TRINITY BIOTECH PLC-SPON ADR
Rating: 3.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to TRIB. TRIB was compared to 189 industry peers in the Health Care Equipment & Supplies industry. TRIB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TRIB is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

TRIB had negative earnings in the past year.

TRIB had a negative operating cash flow in the past year.

TRIB had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of TRIB (-30.78%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-30.78%
ROE	N/A
ROIC	N/A

ROA(3y)-38.57%

ROA(5y)-23.97%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TRIB's Gross Margin of 34.83% is on the low side compared to the rest of the industry. TRIB is outperformed by 72.49% of its industry peers.

TRIB's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	34.83%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.46%

GM growth 5Y-3.74%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.

TRIB has about the same amout of shares outstanding than it did 1 year ago.

TRIB has more shares outstanding than it did 5 years ago.

TRIB has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.86, we must say that TRIB is in the distress zone and has some risk of bankruptcy.

TRIB's Altman-Z score of -0.86 is in line compared to the rest of the industry. TRIB outperforms 41.80% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-0.86

ROIC/WACCN/A

WACC7.42%

2.3 Liquidity

A Current Ratio of 1.28 indicates that TRIB should not have too much problems paying its short term obligations.

With a Current ratio value of 1.28, TRIB is not doing good in the industry: 79.89% of the companies in the same industry are doing better.

A Quick Ratio of 0.68 indicates that TRIB may have some problems paying its short term obligations.

TRIB has a worse Quick ratio (0.68) than 88.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.28
Quick Ratio	0.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TRIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.

The Revenue has grown by 8.31% in the past year. This is quite good.

The Revenue has been decreasing by -7.41% on average over the past years.

EPS 1Y (TTM)16.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-16%

Revenue 1Y (TTM)8.31%

Revenue growth 3Y-8.8%

Revenue growth 5Y-7.41%

Sales Q2Q%18.09%

3.2 Future

Based on estimates for the next years, TRIB will show a very strong growth in Earnings Per Share. The EPS will grow by 34.68% on average per year.

Based on estimates for the next years, TRIB will show a quite strong growth in Revenue. The Revenue will grow by 11.62% on average per year.

EPS Next Y65.8%

EPS Next 2Y34.68%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year10.13%

Revenue Next 2Y11.62%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TRIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TRIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TRIB's earnings are expected to grow with 34.68% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.68%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TRIB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (11/7/2025, 8:22:27 PM)

After market: 0.9451 0 (0%)

0.9451

-0.01 (-1.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-13 2025-08-13/bmo

Earnings (Next)04-03 2026-04-03/bmo

Inst Owners0.87%

Inst Owner Change1.97%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap18.14M

Revenue(TTM)61.56M

Net Income(TTM)-31.79M

Analysts85.71

Price TargetN/A

Short Float %14.41%

Short Ratio0.09

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-128.03%

Min EPS beat(2)-272.55%

Max EPS beat(2)16.49%

EPS beat(4)1

Avg EPS beat(4)-116.51%

Min EPS beat(4)-272.55%

Max EPS beat(4)16.49%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-7.88%

Min Revenue beat(2)-9.97%

Max Revenue beat(2)-5.78%

Revenue beat(4)0

Avg Revenue beat(4)-6.76%

Min Revenue beat(4)-9.97%

Max Revenue beat(4)-1.38%

Revenue beat(8)1

Avg Revenue beat(8)-7.57%

Revenue beat(12)1

Avg Revenue beat(12)-11.44%

Revenue beat(16)3

Avg Revenue beat(16)-13.23%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.29
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2.68

EYN/A

EPS(NY)-0.92

Fwd EYN/A

FCF(TTM)-0.74

FCFYN/A

OCF(TTM)-0.22

OCFYN/A

SpS3.21

BVpS-1.83

TBVpS-4.51

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.78%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	34.83%
FCFM	N/A

ROA(3y)-38.57%

ROA(5y)-23.97%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.46%

GM growth 5Y-3.74%

F-Score4

Asset Turnover0.6

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	539.63%
Cap/Sales	16.35%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.28
Quick Ratio	0.68
Altman-Z	-0.86

F-Score4

WACC7.42%

ROIC/WACCN/A

Cap/Depr(3y)316%

Cap/Depr(5y)319.23%

Cap/Sales(3y)10.22%

Cap/Sales(5y)10.28%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)16.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-16%

EPS Next Y65.8%

EPS Next 2Y34.68%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)8.31%

Revenue growth 3Y-8.8%

Revenue growth 5Y-7.41%

Sales Q2Q%18.09%

Revenue Next Year10.13%

Revenue Next 2Y11.62%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-12.19%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y0.04%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y63.74%

OCF growth 3YN/A

OCF growth 5YN/A

TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ

What is the ChartMill fundamental rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TRIB.

What is the valuation status for TRIB stock?

ChartMill assigns a valuation rating of 1 / 10 to TRINITY BIOTECH PLC-SPON ADR (TRIB). This can be considered as Overvalued.

What is the profitability of TRIB stock?

TRINITY BIOTECH PLC-SPON ADR (TRIB) has a profitability rating of 1 / 10.

Can you provide the financial health for TRIB stock?

The financial health rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) is 1 / 10.

TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ

What is the ChartMill fundamental rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?

What is the valuation status for TRIB stock?

What is the profitability of TRIB stock?

Can you provide the financial health for TRIB stock?